Dual vs Triple Agonist Peptides: Is More Better?

Multi-Agonism

3.3 percentage points

The incremental weight loss gained by adding a third receptor target (glucagon) to a dual agonist was approximately 3.3 percentage points in Phase 2 data, less than half the gain from adding the second.

Jastreboff et al., NEJM, 2022 & 2023

Jastreboff et al., NEJM, 2022 & 2023

View as image

The obesity drug pipeline has followed a clear trajectory: each generation adds a receptor target. Liraglutide and semaglutide activate GLP-1 receptors only. Tirzepatide activates both GLP-1 and GIP receptors. Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Each step up has produced more weight loss: roughly 8%, then 15%, then 21%, then 24%. The question facing the field is whether a third receptor target justifies the added complexity, cost, and side effect burden. For the broader analysis of where multi-agonism hits a ceiling, see the pillar article in this cluster.

The answer is not straightforward. The data shows that triple agonism produces more weight loss than dual agonism, but the increment is shrinking, and the comparison depends on which specific dual agonist you use as the benchmark.

The Two Approved and Emerging Approaches

The multi-agonist field has produced two distinct strategies for exceeding the efficacy ceiling of single GLP-1 receptor agonists. Understanding the difference is essential for evaluating the dual-versus-triple question.

Strategy 1: GLP-1 + GIP (tirzepatide model). Tirzepatide activates both the GLP-1 receptor (appetite suppression, gastric slowing) and the GIP receptor (glucose-dependent insulin secretion, and emerging evidence for direct effects on adipose tissue and the brain). GIP's role in obesity treatment was controversial when tirzepatide entered trials; GIP receptor activation had historically been associated with fat storage rather than fat loss. Tirzepatide's clinical success overturned this assumption and demonstrated that GIP receptor agonism, in combination with GLP-1, produces weight loss exceeding what either receptor can achieve alone.

Strategy 2: GLP-1 + glucagon (survodutide/mazdutide model). A different dual agonist approach pairs GLP-1 with the glucagon receptor instead of GIP. Glucagon increases hepatic glucose output and energy expenditure, directly boosting caloric burn rather than just suppressing appetite. Survodutide achieved 18.7% weight loss in Phase 2, and mazdutide showed similar results in Chinese populations.^[3][7] For how GLP-1/glucagon dual agonists specifically affect liver fat and MASH, the glucagon component appears to drive unique hepatic benefits.

Strategy 3: GLP-1 + GIP + glucagon (retatrutide model). Retatrutide combines all three, aiming to capture both GIP's insulin-sensitizing effects and glucagon's energy expenditure effects on top of GLP-1's appetite suppression. The hypothesis: three complementary mechanisms produce more than the sum of any two.

Head-to-Head: What the Clinical Data Shows

Tirzepatide: The Dual Agonist Benchmark

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and randomized them to tirzepatide (5, 10, or 15 mg weekly) or placebo for 72 weeks.^[2] Results at the highest dose:

• Mean weight loss: 20.9% (vs. 3.1% placebo)
• 36.2% of participants lost at least 25% of body weight
• Gastrointestinal adverse events were the most common side effect (nausea in 24%, diarrhea in 21%, constipation in 11%)
• Discontinuation due to adverse events: 6.2%

In the head-to-head SURPASS-2 trial, tirzepatide was compared directly to semaglutide 1 mg (not the 2.4 mg obesity dose) in patients with type 2 diabetes.^[4] Tirzepatide at all three doses produced significantly greater HbA1c reductions and weight loss than semaglutide 1 mg. At the 15 mg dose, tirzepatide produced 12.4 kg weight loss versus 6.2 kg for semaglutide 1 mg. This trial established tirzepatide's superiority over a single agonist, though the comparison used a lower semaglutide dose than the obesity-approved 2.4 mg.

Tirzepatide is now FDA-approved for both type 2 diabetes (Mounjaro) and obesity (Zepbound), making it the clinical standard against which triple agonists will be measured.

Retatrutide: The Triple Agonist Contender

Retatrutide's Phase 2 obesity trial enrolled 338 adults and tested five doses (1, 4, 8, and 12 mg weekly) versus placebo for 48 weeks.^[1] Results at the highest dose:

• Mean weight loss: 24.2% (vs. 2.1% placebo)
• 26% of participants at 12 mg lost at least 30% of body weight
• Gastrointestinal adverse events: nausea (26%), diarrhea (22%), vomiting (14%), constipation (11%)
• Discontinuation due to adverse events: approximately 12-18% at higher doses
• Dose-dependent increase in heart rate: up to 4.3 bpm above placebo

The 24.2% weight loss at 48 weeks is the highest reported for any single-molecule obesity treatment in a controlled trial. Preclinical data showed that optimized triple agonists could normalize body weight entirely in obese mice, an effect not achieved by any dual agonist tested in the same models.^[6]

Retatrutide is currently in Phase 3 trials (the TRIUMPH program). The TRIUMPH-5 study will provide the first direct comparison between retatrutide and tirzepatide, which will be the definitive answer to the dual-versus-triple question for these specific drugs.

Survodutide: The Other Dual Agonist

Survodutide takes a different dual approach: GLP-1 plus glucagon, without GIP. Its Phase 2 obesity trial achieved 18.7% weight loss at 4.8 mg weekly over 46 weeks.^[3] This is lower than tirzepatide's 20.9% despite also being a dual agonist. The difference illustrates an important principle: not all dual agonists are equal. The specific receptor combination, the relative potency at each receptor, and the pharmacokinetic profile all determine efficacy.

Survodutide's glucagon component appears to provide unique benefits for liver fat reduction. Phase 2 data showed substantial reductions in hepatic fat content, making survodutide a promising candidate for metabolic dysfunction-associated steatohepatitis (MASH), a condition where GLP-1-only agonists show more modest effects.

The Incremental Gain Is Shrinking

The core question is whether the jump from dual to triple agonism justifies the tradeoffs. The data reveals a pattern of diminishing returns:

The increment from single to dual (GLP-1 to GLP-1/GIP): approximately 6 percentage points. The increment from dual to triple (GLP-1/GIP to GLP-1/GIP/glucagon): approximately 3 percentage points. Each added receptor delivers less additional benefit than the last.

A 2026 systematic review and meta-analysis confirmed this pattern across the full landscape of incretin-based multi-agonists.^[5] Chan et al. pooled data from randomized controlled trials of dual and triple agonists in overweight and obese individuals. Triple agonists produced the largest absolute weight reductions, but the incremental advantage over the best dual agonists was smaller than the advantage dual agonists held over single agonists. The review also found that gastrointestinal adverse event rates increased with the number of receptor targets.

For how single molecule approaches compare to combination therapy (combining two separate drugs rather than engineering one molecule that hits multiple receptors), the multi-agonist strategy has the advantage of a single injection and coordinated pharmacokinetics but may sacrifice the ability to independently adjust doses for each receptor.

Side Effects Scale with Receptor Count

Each receptor target contributes its own adverse effect profile:

GLP-1 receptor: Nausea, vomiting, decreased appetite, constipation. These are the most common side effects of all drugs in this class and are dose-dependent.

GIP receptor: The GIP component of tirzepatide does not appear to significantly worsen gastrointestinal side effects beyond what GLP-1 alone causes. GIP may actually buffer some GLP-1-mediated nausea, though the mechanism is not fully understood.

Glucagon receptor: Increases hepatic glucose output (potentially worsening blood sugar control in diabetic patients), increases heart rate, and may add to gastrointestinal symptoms. The heart rate increase with retatrutide (up to 4.3 bpm) exceeds what is seen with GLP-1-only or GLP-1/GIP drugs.

The practical consequence: discontinuation rates climb with each added receptor. Semaglutide 2.4 mg in STEP trials had discontinuation rates around 5-7%. Tirzepatide in SURMOUNT-1 was at 6.2%. Retatrutide in Phase 2 reached 12-18% at higher doses. If Phase 3 confirms these rates, a substantial fraction of patients prescribed triple agonists will not tolerate them long enough to achieve maximum benefit.

For context on other tradeoffs in GLP-1 therapy, see GLP-1 Weight Loss and Sarcopenia: The Hidden Risk in Older Adults and Does Semaglutide Change Your Body Composition?. Muscle loss during rapid weight loss may be exacerbated by more potent multi-agonists, though this has not been directly studied for retatrutide.

What TRIUMPH-5 Will Answer

The ongoing TRIUMPH-5 trial is a head-to-head comparison of retatrutide versus tirzepatide in adults with obesity. This trial will provide the first direct, randomized comparison between the leading dual and triple agonist, controlling for patient population, trial duration, and measurement methods.

Until TRIUMPH-5 reports, the comparison between tirzepatide (SURMOUNT-1) and retatrutide (Phase 2) is indirect. The two trials enrolled different populations, used different dose titration schedules, and ran for different durations (72 weeks for tirzepatide versus 48 weeks for retatrutide). The 24.2% figure for retatrutide may change in either direction when Phase 3 data in larger populations over longer treatment periods becomes available.

What TRIUMPH-5 will clarify: whether the approximately 3 percentage point advantage of triple over dual agonism observed in Phase 2 holds in a direct comparison, whether the side effect differential is clinically meaningful, and whether specific subpopulations (e.g., patients with fatty liver disease or insulin resistance) benefit disproportionately from the glucagon receptor component. For more on the science behind why multi-agonism produces additional weight loss, the mechanisms are complementary rather than redundant.

When Dual May Be Enough

The pragmatic question for clinicians and patients is not which drug produces the most weight loss in a clinical trial, but which drug produces enough weight loss with acceptable tolerability for a given individual. Several factors favor dual over triple agonism for many patients:

The tolerability advantage. If 12-18% of patients discontinue retatrutide due to side effects versus 6% for tirzepatide, the population-level benefit of triple agonism is smaller than the individual-level trial data suggests. A drug that a patient can tolerate and take consistently will outperform a more potent drug that causes intolerable nausea after two months.

Cost and access. Multi-agonists are expensive to develop and manufacture. Triple agonists will likely carry premium pricing. If tirzepatide achieves 21% weight loss and retatrutide achieves 24%, the cost-effectiveness calculation for that additional 3 percentage points may not favor the triple agonist for most patients.

The 20% threshold. Clinical research suggests that 15-20% weight loss is sufficient to resolve or substantially improve most obesity-related comorbidities (sleep apnea, type 2 diabetes, hypertension, fatty liver). If tirzepatide already crosses this threshold for most patients, the marginal clinical benefit of an additional 3% body weight loss may be limited for comorbidity resolution.

Specific indications. Triple agonism's advantage may be most relevant for patients with severe obesity (BMI greater than 50) who need maximum weight loss, or for patients with MASH where the glucagon component provides unique hepatic benefits not achievable with GIP-based dual agonists. For how CagriSema takes a different combination approach by pairing GLP-1 with amylin rather than adding more incretin receptor targets, the combination strategy landscape extends beyond the GLP-1/GIP/glucagon axis.

The Bottom Line

Triple agonists (retatrutide) produce approximately 3 percentage points more weight loss than the best dual agonists (tirzepatide) in current trial data, extending the pattern of incremental gains from adding receptor targets. The increment from dual to triple is smaller than the increment from single to dual, consistent with diminishing returns. Side effects and discontinuation rates increase with each added target. The TRIUMPH-5 head-to-head trial will provide definitive comparison data. For most patients, the question is not which drug is maximally potent but which achieves clinically meaningful weight loss with tolerable side effects, and for many, dual agonism may be sufficient.

Frequently Asked Questions

What is a dual agonist peptide?

A dual agonist is a single molecule designed to activate two different hormone receptors simultaneously. Tirzepatide, the first approved dual agonist for obesity, activates both the GLP-1 receptor (which suppresses appetite) and the GIP receptor (which improves insulin sensitivity and may affect fat tissue). It achieved 20.9% mean weight loss in the SURMOUNT-1 trial of 2,539 adults (Jastreboff et al., NEJM, 2022).

What is the difference between tirzepatide and retatrutide?

Tirzepatide is a dual GLP-1/GIP receptor agonist approved for diabetes and obesity. Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist currently in Phase 3 trials. Retatrutide adds glucagon receptor activation, which increases energy expenditure and may provide liver-specific benefits. In Phase 2, retatrutide achieved 24.2% weight loss versus tirzepatide's 20.9%, but with higher discontinuation rates (12-18% vs 6.2%).

Is retatrutide more effective than tirzepatide for weight loss?

In Phase 2 data, retatrutide produced approximately 3 percentage points more weight loss than tirzepatide's Phase 3 results (24.2% vs 20.9%). However, these numbers come from different trials with different populations and durations. The TRIUMPH-5 trial, a head-to-head comparison currently underway, will provide the first direct answer. Phase 3 results may shift retatrutide's efficacy figure in either direction.

What are the side effects of triple agonist peptides?

Triple agonists like retatrutide cause gastrointestinal side effects similar to but more frequent than dual agonists: nausea (26%), diarrhea (22%), vomiting (14%), and constipation (11%) at the highest dose. The glucagon component adds a dose-dependent increase in heart rate (up to 4.3 bpm). Discontinuation rates of 12-18% at higher doses exceed the 5-7% seen with single GLP-1 agonists.

What is survodutide and how does it compare?

Survodutide is a dual GLP-1/glucagon receptor agonist (no GIP) that achieved 18.7% weight loss in Phase 2. It uses a different second receptor than tirzepatide (glucagon instead of GIP), demonstrating that not all dual agonists perform equally. Survodutide's glucagon component may provide unique benefits for liver fat reduction, making it promising for MASH treatment (le Roux et al., Lancet D&E, 2024).

When will retatrutide be available?

Retatrutide is in Phase 3 clinical trials (the TRIUMPH program) as of early 2026. If Phase 3 results are positive, FDA approval could follow in 2027-2028, though timelines can shift based on trial outcomes and regulatory review. The TRIUMPH-5 head-to-head comparison with tirzepatide will be a key dataset for the approval decision.